The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma

• Published in: Journal of clinical oncology Vol. 6; no. 6; p. 983
• Main Authors: Piver, M S, Lele, S B, Marchetti, D L, Baker, T R, Tsukada, Y, Emrich, L J
• Format: Journal Article
• Language: English
• Published: United States 01.06.1988
• Subjects: Adenocarcinoma - mortality; Adenocarcinoma - therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cisplatin - adverse effects; Cisplatin - therapeutic use; Combined Modality Therapy; Cyclophosphamide - adverse effects; Cyclophosphamide - therapeutic use; Doxorubicin - adverse effects; Doxorubicin - therapeutic use; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms - mortality; Ovarian Neoplasms - therapy

Forty consecutive patients with stage III and IV invasive ovarian carcinoma were treated on a phase II protocol consisting of optimal debulking surgery, induction cisplatin, cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy, 6-month interval laparoscopy, reinduction cisplatin, PAC chem...